NICE recommends capivasertib for advanced breast cancer

Clinical trial results revealed that capivasertib, taken with fulvestrant, can provide advanced breast cancer patients with an additional four months before their cancer progresses.
A doctor examines a mammogram for breast cancer

The National Institute for Health and Care Excellence (NICE) has recommended a new combination treatment for locally advanced or metastatic hormone receptor (HR)-positive, HER 2-negative breast cancer for use on the NHS in England and Wales.

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Last updated